STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls

Shattuck Labs (STTK) announced its decision to discontinue the development of its pipeline candidate SL172154, which was being developed for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS), types of blood cancer, as part of its strategic pipeline prioritization efforts. This disappointed investors as SL-172154 was the only clinical-stage candidate in Shattuck's pipeline. Following the news, the stock plummeted 45% on Tuesday and lost another 3.7% during the after-market hours ...